Announcement
05 Jun 2020
In June 2020, the Norwegian authorities introduced an export notification requirement on rivaroxaban, edoxaban, Bacillus Calmette-Guérin, rasburicase and lacosamide due to concerns of domestic shortages following the COVID-19 pandemic.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
05 Jun 2020
Revocation date:
01 Jul 2023
Updated: 05 Jun 2020
Export licensing requirement
On 5 June 2020, the Norwegian Medicines Agency introduced a notification requirement on exports of rivaroxaban, edoxaban, Bacillus Calmette-Guérin, rasburicase and lacosamide following the COVID-19...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.